Navigation Links
Particle Sciences Expands Its Combination Product Capabilities
Date:8/19/2008

BETHLEHEM, Pa., Aug. 19 /PRNewswire/ -- Particle Sciences Inc. has expanded its Combination Product (drug-eluting polymers) development and pilot production capabilities with the installation of a compounding, extrusion and injection molding line. The core of the pilot line, comprising a Haake twin-screw compounding extruder and Nissei 20T injection molder, enables the production of high-quality drug loaded polymeric devices. This addition gives Particle Sciences the ability to go from bench scale to clinical trial material production. Particle Sciences has recently completed Phase I of the development of a drug-eluting polymeric vaginal ring that demonstrated 30-day continuous release of a small molecule API. Particle Sciences has also developed and successfully demonstrated a proprietary approach to achieving zero-order release from polymeric drug delivery devices. "The installation of this line, and our continuing investment in related intellectual property, increases our capabilities, and positions Particle Sciences as an innovative developer of drug-eluting medical devices," commented Dr. Andrew Loxley, Director of New Technologies. "And coupled with our recently expanded clean room facilities, will allow us to provide our clients with Combination Product development services from conception through to clinical trials." For more information visit http://www.particlesciences.com

Particle Sciences is an integrated provider of drug development services. Particle Sciences focuses on emulsions, gels, particulates and drug/device combination products with additional specialized capabilities in topical and mucosal drug delivery. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.

Contact: Maureen Cochran 610-861-4701


'/>"/>
SOURCE Particle Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Ion Mobility Diagnostic Test from Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds
2. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
3. Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)
4. IBA and Elekta Initiate Global Particle Therapy Program at ASTRO
5. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
6. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
7. Light Sciences Oncology Raises $40.1 Million in Series C Financing
8. Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate
9. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
10. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
11. Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... 30, 2016 According ... Biometrics Market by Technology (Single-factor (Fingerprint, Face, ... Application (Workforce Management), End User (Hospitals, Healthcare ... by MarketsandMarkets, the market is projected to ... USD 1,182.6 Million by 2016, at a ...
(Date:5/30/2016)... - DCGI grants limited approval to market Stempeucel® product for ... Stempeucel® becomes 5th off-the-shelf Stem cell product to be approved by ... Disease (also known as Thromboangiitis Obliterans) is a major unmet medical ... - Prevalence of Buerger,s Disease is estimated to be 1,000,000 in ... the European Community & USA ...
(Date:5/27/2016)... LabStyle Innovations Corp . ( ... today announced that the Company,s Chief Financial Officer, Zvi ... held June 1-2 in New York, NY ... in Los Angeles, CA. ... operational milestones, including the U.S. FDA Clearance and commercial launch ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... Presence Technology ... has been included by Gartner, Inc. in the Contact Center Infrastructure Magic Quadrant ... Center Infrastructure technologies, some of which include: Computer-telephony integration (CTI)/Web services interfaces, ...
(Date:5/31/2016)... Beach, Florida (PRWEB) , ... May 31, 2016 ... ... to Jay Butch of CertainTeed Corporation, he knew it was something that contractors ... as state-of-the-art and cutting-edge as it gets,” says Butch, CertainTeed’s Director of Contractor ...
(Date:5/31/2016)... Switzerland (PRWEB) , ... May 31, 2016 , ... The ... this model in their laboratories as well. However, laboratories have different challenges compared to ... benefits of lean operations in the lab, METTLER TOLEDO has developed the Lean ...
(Date:5/31/2016)... ... 2016 , ... Spectrum Aquatics has launched a brand new ADA pool lift, ... with the user in mind. , “Over the last two years our key customers ... 400 lbs lift is a necessary requirement for certain facilities with specific needs,” said ...
(Date:5/31/2016)... ... ... a recent interview on The Greenburgh Report radio show hosted by Greenburgh, NY Town ... leading medical insurance advocate Adria Goldman Gross discussed several eye-opening issues that have combined ... the interview with Mr. Feiner that aired on May 7, 2016, Ms. Gross, the ...
Breaking Medicine News(10 mins):